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LETTER TO THE EDITOR
Blood Transfusion and
Colorectal Cancer
Outcome
To the Editor:
A cheson et al conclude that patients whoundergo colorectal surgery for cancer
have an increased risk of overall mortality
and cancer mortality if they receive allo-
genic red blood cell transfusions.1 But do
they have the cart before the horse? Their
study, a systematic review of the literature,
reviewed 20,795 patients with colorectal can-
cer of which 59% were transfused in the pe-
rioperative period. These patients were com-
pared with the 41% of nontransfused patients.
Although the authors attempted to adjust for
various risk factors that might lead to trans-
fusion, such matching is bound to be prob-
lematic. For example, it appears that only 1
of the 55 included studies adjusted for blood
loss, and only 1 study adjusted for the type of
surgeon. Although the authors point out that
allogenic blood transfusions may be deleteri-
ous, it is important to consider that the factors
that predispose patients to transfusion are the
real cause of the adverse outcome, rather than
the use of blood. Neovascularization seen in
later stage tumors may affect total blood loss
during surgery. Intraoperative complications
and surgeon experience may also contribute to
blood loss and the decision to transfuse. Any
of these factors will contribute to increased
risk of mortality and long-term survival.
Although a randomized controlled trial
based on use or nonuse of transfusion would
be unethical, a substitute trial comparing au-
tologous with allogenic transfusion in patients
with colorectal cancer has been performed
and revealed no difference in outcome in the
2 groups after 4 years, suggesting that blood
loss rather than transfusion is the major cause
leading to increased mortality.2 In a recent
report, Morner et al3 also suggest that blood
loss is the driving force—not transfusion.
In summary, all surgeons understand
the importance of minimizing blood loss dur-
ing colorectal surgery, but we believe that
if transfusion becomes necessary, it will not
jeopardize the patient’s life.
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Reply:
W e were interested to read the recentcomments from Albert Lowenfels et
al in response to the article “Effects of Al-
logeneic Red Blood Cell Transfusions on
Clinical Outcomes in Patients Undergoing
Colorectal Cancer Surgery: A Systematic Re-
view and Meta-analysis.”1 The original ar-
ticle did not advocate withholding allogeneic
blood transfusions (ABTs) when clinically re-
quired but illustrated that the clinician must
be mindful of the potential repercussions that
such transfusions may have.
Lowenfels et al make the comment
that increased ABT use may be indicative of
higher blood losses, which may be a conse-
quence of more advanced tumor, more techni-
cally challenging surgery, or lack of surgical
experience/expertise. Although it is true that
such factors were not matched in all the lit-
erature reviewed in the original article, we
would argue that with the advent of colorec-
tal screening programs, minimal access ap-
proaches, and increased trainee supervision,
such factors would account for exceptions in
ABT, rather than the norm.
We feel that the majority of perioper-
ative ABT use is a consequence of preexist-
ing, preoperative anemia, which in itself re-
sults in an increase in perioperative mortal-
ity and morbidity,2 rather than intraoperative
blood loss. It is suggested that 39% of patients
with a diagnosis of colorectal cancer will have
anemia.3 Such a figure mirrors the 41% ABT
rate identified in our original article, which
is far higher than the number of operative
cases that would be expected to have signif-
icant blood loss to require ABT, irrespective
of causality.
Lowenfels et al also propose that the
study by Busch et al4 lends weight to the argu-
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ment that blood loss is the major factor lead-
ing to increased mortality, where equal mor-
tality rates were seen after autologous blood
transfusion and ABT use in patients who un-
derwent colorectal cancer surgery. Although
this may be contributory, we believe that there
still remains insufficient clinical evidence to
state that autologous blood transfusion does
not merely produce the same adverse clinical
outcomes as ABT although the risks of infec-
tion transmission are likely to be reduced by
this strategy.5
Mortality after surgery for colorectal
malignancy is clearly multifactorial. We ad-
vocate measures to treat preoperative anemia
and limit perioperative losses, and when all
else fails, use restrictive ABT practices, aware
that this is a risk-benefit decision.6
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